Y-mAbs Therapeutics Inc.

750 Third Avenue, 9th Floor
New York
New York
10017
United States

Tel: 212-847-9841

About Y-mAbs Therapeutics Inc.

YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7-H3. To further improve our bispecific antibodies, we are collaborating with MSK on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.
YEAR FOUNDED:
April 2014
LEADERSHIP:
Founder, President and Head of Business Development and Strategy: Thomas Gad
CEO: Claus Moller
CFO: Bo Kruse
SVP, Head of Technical Operations: Torben Lund-Hansen, PhD
SVP, CMO: Ole Baadsgaard, MD, DMSc
CAREER:
Please click here for YmAbs' job opportunities.

131 articles about Y-mAbs Therapeutics Inc.

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

2/17/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets.
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

2/11/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it recently completed a Pre-Biologics License Application (“pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma.
Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

1/5/2022

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that its Chief Executive Officer, Dr. Claus Moller, MD, Ph.D., will provide an overview and update on the Company's business at the virtual 40th Annual J.P. Morgan Healthcare Conference.
Y-mAbs Announces Pipeline Update - Dec 15, 2021

12/15/2021

Y-mAbs Therapeutics, Inc. announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.
UPDATE - Y-mAbs Announces Pipeline Update

12/15/2021

Y-mAbs Therapeutics, Inc. today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.
Y-mAbs Hosting Virtual Research and Development Day

12/6/2021

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time.
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis

11/4/2021

Y-mAbs Therapeutics, Inc. announced that, based on feedback from the U.S. Food and Drug Administration at a recent Type B meeting, where the Company provided the FDA with additional detailed data and the statistical analysis plan, the Company has requested a pre-BLA meeting for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments

11/4/2021

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the third quarter of 2021.
Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

10/28/2021

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets.
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA

10/7/2021

Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation (“RPDD”) for the Company’s lutetium labelled omburtamab antibody program for the treatment of medulloblastoma.
Y-mAbs Announces Data to be Presented at SIOP 2021

9/16/2021

Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of two presentations at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 21 through October 24, 2021.
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

9/13/2021

Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has been granted priority review of the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk).
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

9/10/2021

Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) today announced that it will host a key opinion leader ("KOL") webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma on Thursday, September 23, 2021 at 12 p.m. ET.
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

8/5/2021

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter of 2021.
Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

7/29/2021

Y-mAbs Therapeutics, Inc. announced that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets.
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

7/6/2021

Y-mAbs Therapeutics, Inc. today announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory neuroblastoma.
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

6/25/2021

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma.
Y-mAbs Announces Update on Omburtamab for DIPG

6/4/2021

Y-mAbs Therapeutics, Inc. announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine will present interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma at the American Society of Clinical Oncology Virtual Annual Meeting on June 4, 2021.
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma

6/4/2021

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children's Hospital will present frontline data for DANYELZA
Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

5/19/2021

Y-mAbs Therapeutics, Inc. announced that it has entered into an exclusive distribution agreement with Adium Pharma S.A. to be the exclusive distributor in Latin America of the Company’s antibodies, DANYELZA® for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.